The **only** sublingual grass allergy immunotherapy tablet with a mixed pollens allergen extract from 5 grasses

• An important immunotherapy option for patients with grass allergies
• Effective during the first pollen season
• Demonstrated safety profile

Visit ORALAIR.com to learn more.

Initiate treatment with ORALAIR® 4 months before the expected onset of each grass pollen season and maintain it throughout the grass pollen season.

**Indications and Usage**

ORALAIR® is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the 5 grass species contained in this product. ORALAIR is approved for use in persons 10 through 65 years of age.

ORALAIR is not indicated for the immediate relief of allergy symptoms.

**Important Safety Information**

**WARNING: SEVERE ALLERGIC REACTIONS**

• ORALAIR can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal edema.
• Do not administer ORALAIR to patients with severe, unstable or uncontrolled asthma.
• Observe patients in the office for at least 30 minutes following the initial dose.
• Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.
• ORALAIR may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.
• ORALAIR may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

Please see additional Important Safety Information on last page. Please see full Prescribing Information, including Boxed Warning and Medication Guide, at ORALAIR.com.
Important Safety Information

WARNING: SEVERE ALLERGIC REACTIONS

• ORALAIR® can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal edema.
• Do not administer ORALAIR to patients with severe, unstable or uncontrolled asthma.
• Observe patients in the office for at least 30 minutes following the initial dose.
• Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.
• ORALAIR may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.
• ORALAIR may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

ORALAIR is contraindicated in patients with severe, unstable or uncontrolled asthma, patients with a history of any severe systemic allergic reaction or severe local reaction to sublingual allergen immunotherapy or of eosinophilic esophagitis, or patients who are hypersensitive to any of the inactive ingredients.

ORALAIR can cause systemic allergic reactions, including anaphylaxis, and severe local reactions, including laryngopharyngeal swelling, which may be life-threatening. Severe and serious allergic reactions may require treatment with epinephrine. Patients who have a systemic allergic reaction to ORALAIR should stop taking the product. Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy. Discontinue ORALAIR in patients with persistent symptoms of eosinophilic esophagitis, including dysphagia or chest pain. ORALAIR treatment should be withheld if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ORALAIR. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.

In case of oral inflammation or wounds, such as following oral surgery or dental extraction, ORALAIR treatment should be discontinued to allow complete healing of the oral cavity. The risk of ORALAIR may be increased when treatment is initiated during the grass pollen season.

The most common adverse events reported in ≥5% of patients were oral pruritus, throat irritation, ear pruritus, mouth edema, tongue pruritus, cough, and oropharyngeal pain. Patients who have escalating or persistent local reactions to ORALAIR should be reevaluated and considered for discontinuation of ORALAIR.

ORALAIR should be used during pregnancy or breastfeeding only if clearly needed.

Please see accompanying full Prescribing Information, including Boxed Warning and Medication Guide.

### Patient Information

- **Patient Name:** __________________________________________
- **Address:** ______________________________________________
- **City, State, Zip:** _________________________________________
- **Primary Phone:** _______________ **Alternate Phone:** ___________
- **Date of Birth:** _________________ **Gender:** ___________________
- **Medication Allergies:** _____________________________________
- **E-mail:** _________________________________________________
- **Last 4 Digits of Social Security Number:** ______________________

### Prescriber Information

- **Prescriber’s First Name:** ________________________
- **Prescriber’s Last Name:** ___________________________________
- **State License Number:** ____________________________________
- **NPI Number:** ________________ **DEA Number:** ________________
- **Address:** _______________________________________________
- **City, State, Zip:** _________________________________________
- **Phone:** ______________________ **Fax:** _______________________

### Delivery/Shipment Options

- **Ship to Patient’s Home:** [ ]
- **Other:** ____________________

### Insurance Information

**Diagnosis and Clinical Information**

- **Prescription Card (Drug Insurance):**
  - Q J30.1 Allergic Rhinitis due to Pollen
  - Other: ______________________________________________

- **Name of Insurer:** ________________________________________
- **ID Number:** ____________________________________________
- **BIN:** __________________________________________________
- **PCN:** _________________________________________________
- **Group:** ________________________________________________

Please copy the front and back of insurance card and ORALAIR co-pay card (if patient has one), and attach all pages to this form.

### Prescription Information

- **Dispenser:**
- **Date:** ____________________________

**Substitution allowed** _________________________________________________________________________________________

**IMPORTANT NOTICE:** This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee. Please see Important Safety Information on last page. Please see full Prescribing Information, including Boxed Warning and Medication Guide, at ORALAIR.com.

---

### Form Instructions

- This form is to be used when faxing directly to a specialty pharmacy within the ORALAIR® network of pharmacies.
- Please copy the front and back of insurance card and ORALAIR co-pay card (if patient has one), and attach all pages to this form.
- **Dispenser’s Signature Required:**
- **Date:** ____________________________

**Dispense as written** ______________________________________

**Substitution allowed** _________________________________________________________________________________________

**IMPORTANT NOTICE:** This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee. Please see Important Safety Information on last page. Please see full Prescribing Information, including Boxed Warning and Medication Guide, at ORALAIR.com.
Important Safety Information

WARNING: SEVERE ALLERGIC REACTIONS

• ORALAIR can cause life-threatening allergic reactions such as anaphylaxis and severe laryngeal edema.
• Do not administer ORALAIR to patients with severe, unstable or uncontrolled asthma.
• Observe patients in the office for at least 30 minutes following the initial dose.
• Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.
• ORALAIR may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.
• ORALAIR may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators.

ORALAIR is contraindicated in patients with severe, unstable or uncontrolled asthma, patients with a history of any severe systemic allergic reaction or severe local reaction to sublingual allergen immunotherapy or of eosinophilic esophagitis, or patients who are hypersensitive to any of the inactive ingredients.

ORALAIR can cause systemic allergic reactions, including anaphylaxis, and severe local reactions, including laryngeal edema, swelling in the throat or pharynx, tongue pruritus, cough, and oropharyngeal pain. Patients who have escalating or persistent local reactions to ORALAIR should be reevaluated and considered for discontinuation of ORALAIR.

Tongue swelling, which may be life-threatening. Severe and serious allergic reactions may require treatment with epinephrine. Patients who have a systemic allergic reaction to ORALAIR should stop taking the product. Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy. Discontinue ORALAIR in patients with persistent symptoms of eosinophilic esophagitis, including dysphagia or chest pain. ORAL AIR treatment should be withheld if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ORALAIR.

Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.

In case of oral inflammation or wounds, such as following oral surgery or dental extraction, ORALAIR treatment should be withheld if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ORALAIR.

The most common adverse events reported in 5% of patients were oral pruritus, throat irritation, ear pruritus, mouth edema, tongue pruritus, cough, and oropharyngeal pain. Patients who have escalating or persistent local reactions to ORALAIR should be reevaluated and considered for discontinuation of ORALAIR.

ORALAIR should be used during pregnancy or breastfeeding only if clearly needed.

Please see accompanying full Prescribing Information, including Boxed Warning and Medication Guide.


Stallergenes Greer 800-237-2767 • Fax referral to: 800-323-2445

For more information, please visit www.stallergenes.com

Please see indications and Usage and additional Important Safety Information on reverse side. Please see accompanying full Prescribing Information, including Boxed Warning and Medication Guide.

Important Safety Information

WARNING: SEVERE ALLERGIC REACTIONS

• ORALAIR can cause life-threatening allergic reactions such as anaphylaxis and severe laryngeal edema.
• Do not administer ORALAIR to patients with severe, unstable or uncontrolled asthma.
• Observe patients in the office for at least 30 minutes following the initial dose.
• Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.
• ORALAIR may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.
• ORALAIR may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

ORALAIR is contraindicated in patients with severe, unstable or uncontrolled asthma, patients with a history of any severe systemic allergic reaction or severe local reaction to sublingual allergen immunotherapy or of eosinophilic esophagitis, or patients who are hypersensitive to any of the inactive ingredients.

ORALAIR can cause systemic allergic reactions, including anaphylaxis, and severe local reactions, including laryngeal edema, swelling in the throat or pharynx, tongue pruritus, cough, and oropharyngeal pain. Patients who have escalating or persistent local reactions to ORALAIR should be reevaluated and considered for discontinuation of ORALAIR.

Tongue swelling, which may be life-threatening. Severe and serious allergic reactions may require treatment with epinephrine. Patients who have a systemic allergic reaction to ORALAIR should stop taking the product. Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy. Discontinue ORALAIR in patients with persistent symptoms of eosinophilic esophagitis, including dysphagia or chest pain. ORAL AIR treatment should be withheld if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ORALAIR.

Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.

In case of oral inflammation or wounds, such as following oral surgery or dental extraction, ORALAIR treatment should be withheld if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ORALAIR.

The most common adverse events reported in 5% of patients were oral pruritus, throat irritation, ear pruritus, mouth edema, tongue pruritus, cough, and oropharyngeal pain. Patients who have escalating or persistent local reactions to ORALAIR should be reevaluated and considered for discontinuation of ORALAIR.

ORALAIR should be used during pregnancy or breastfeeding only if clearly needed.

Please see accompanying full Prescribing Information, including Boxed Warning and Medication Guide.

**Important Safety Information**

**WARNING: SEVERE ALLERGIC REACTIONS**

- ORALAIR® can cause life-threatening allergic reactions such as anaphylaxis and severe laryngeal edema.
- Do not administer ORALAIR® to patients with severe, unstable or uncontrolled asthma.
- Observe patients in the office for at least 30 minutes following the initial dose.
- Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.
- ORALAIR® may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.
- ORALAIR® may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

**ORALAIR® is contraindicated in patients with severe, unstable or uncontrolled asthma, patients with a history of any severe systemic allergic reaction to any local reaction to sublingual allergen immunotherapy or of eosinophilic esophagitis, or patients who are hypersensitive to any of the inactive ingredients.**

- ORALAIR® can cause systemic allergic reactions, including anaphylaxis, and severe local reactions, including laryngeal edema, wheezing or life-threatening asthma.
- Severe and systemic reactions may require treatment with epinephrine. Patients who have a systemic allergic reaction to ORALAIR® should stop taking the product.
- Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy. Discontinue ORALAIR® in patients with persistent symptoms of eosinophilic esophagitis, including dysphagia or chest pain. ORALAIR treatment should be withheld if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ORALAIR®.
- Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.

- In case of oral inflammation or wounds, such as following oral surgery or dental extraction, ORALAIR treatment should be withheld if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ORALAIR®.

- The most common adverse events reported in ≥5% of patients were oral pruritus, throat irritation, ear pruritus, mouth edema, tongue pruritus, cough, and oropharyngeal pain. Patients who have escalating or persistent local reactions to ORALAIR should be reevaluated and considered for discontinuation of ORALAIR.

- In patients who are hypersensitive to any of the inactive ingredients.

- ORALAIR® is contraindicated in patients with severe, unstable or uncontrolled asthma, patients with a history of any severe systemic allergic reaction to any local reaction to sublingual allergen immunotherapy or of eosinophilic esophagitis, or patients who are hypersensitive to any of the inactive ingredients.

- ORALAIR® can cause systemic allergic reactions, including anaphylaxis, and severe local reactions, including laryngeal edema, wheezing or life-threatening asthma.
- Severe and systemic reactions may require treatment with epinephrine. Patients who have a systemic allergic reaction to ORALAIR® should stop taking the product.
- Eosinophilic esophagitis has been reported in association with sublingual tablet immunotherapy. Discontinue ORALAIR® in patients with persistent symptoms of eosinophilic esophagitis, including dysphagia or chest pain. ORALAIR treatment should be withheld if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ORALAIR®.
- Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.

- In case of oral inflammation or wounds, such as following oral surgery or dental extraction, ORALAIR treatment should be withheld if the patient is experiencing an acute asthma exacerbation. Re-evaluate patients who have recurrent asthma exacerbations and consider discontinuation of ORALAIR®.

- The most common adverse events reported in ≥5% of patients were oral pruritus, throat irritation, ear pruritus, mouth edema, tongue pruritus, cough, and oropharyngeal pain. Patients who have escalating or persistent local reactions to ORALAIR should be reevaluated and considered for discontinuation of ORALAIR.

- ORALAIR® should be used during pregnancy or breastfeeding only if clearly needed.

- ORALAIR® is not indicated for the immediate relief of allergy symptoms.

**Important Safety Information**

**WARNING: SEVERE ALLERGIC REACTIONS**

- ORALAIR® can cause life-threatening allergic reactions such as anaphylaxis and severe laryngopharyngeal edema.
- Do not administer ORALAIR® to patients with severe, unstable or uncontrolled asthma.
- Observe patients in the office for at least 30 minutes following the initial dose.
- Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use.
- ORALAIR® may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious allergic reaction.
- ORALAIR® may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

**ORALAIR® is a registered trademark of Stallergenes Greer or its affiliates.**

**Stallergenes Greer** PO Box 800, 639 Nuway Circle NE, Lenoir, NC 28645 1-844-672-5247 © Stallegenes Greer 2016. All Rights Reserved. MPN 072816H1929 08.16 5K